Abstract: Medication non-adherence in patients with schizophrenia continues to be a significant problem and threatens successful treatment outcomes. Medication non-adherence is often associated with negative consequences, including symptom exacerbation, more frequent emergency room visits, re-hospitalizations and relapse. Long-acting injectable (LAI) forms of antipsychotics allow for rapid identification of non-adherence, obviate the need for the patient to take the medication on a daily basis and increase adherence to some significant degree. Eli Lilly has developed a long-acting depot formulation of olanzapine, olanzapine pamoate, which has recently been approved by the FDA for the US market, and which will be reviewed here. Olanzapine LAI appears to be an effective antipsychotic at dosages of 210 mg every 2 weeks, 300 mg every 2 weeks and 405 mg every 4 weeks in patients with acute schizophrenia, and at 150 mg every 2 weeks, 300 mg every 2 weeks and at 405 mg every 4 weeks for the maintenance treatment of stable patients. Oral supplementation appears not to be needed, particularly not at the onset of treatment with the LAI as is necessary with risperidone LAI. Its efficacy is in general comparable to the efficacy seen with oral olanzapine at a corresponding dose. The side effect profile is also comparable to the side effects observed with oral olanzapine, including lower rates of extrapyramidal symptoms, prolactin elevation and cardiovascular side effects, but significant metabolic effects. The latter include significant weight gain, lipid abnormalities and glucose dysregulation. While the injection site adverse events are overall mild, the most significant serious adverse event is the post-injection delirium sedation syndrome (PDSS). While rare, this syndrome results from inadvertent intravascular injection of olanzapine LAI and can cause a range of olanzapine overdose-type of symptoms. Olanzapine LAI needs therefore to be administered by trained personnel in settings where a post-injection observation period for at least 3 hours by medical personnel is available. The overall use of olanzapine LAI will probably be limited by the possibility of a PDSS event. Patients who have a history of good response to oral olanzapine and are in need of assured medication administration may present a good indication for its use, provided that the appropriate mental health delivery setting is available.
Introduction
Medication non-adherence in patients with schizophrenia continues to be a significant problem and threatens successful treatment outcomes. 1 Reported rates of non-adherence to antipsychotics range from 20% to 69% with an estimated average rate of about 50%. 2, 3 Medication non-adherence is often associated with negative consequences, including symptom exacerbation, more frequent emergency room visits, re-hospitalizations and relapse. 4 Among patients who discontinue their medication, 75% experience significant symptom exacerbation over 1 year compared to 25% of those who adhere to their 
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medication. 4 In turn, symptom exacerbation can often lead to serious consequences, including dangerous behaviors, worsened prognosis of the disease, antipsychotic treatment resistance and increased healthcare costs. 4 Medication status is the largest predictor of relapse risk in schizophrenia with continuous maintenance of antipsychotic medication resulting in an approximate 70% reduction in the risk of relapse. 3, 4 Hence, treatments that can increase medication adherence are critically important in the pharmacological treatment of schizophrenia. Long-acting injectable (LAI) forms of antipsychotics fulfill an important role in this domain of treatment. LAI antipsychotics allow for rapid identification of non-adherence, obviate the need for the patient to take the medication every day and increase adherence to some significant degree. 2, 3 Both typical antipsychotics (fluphenazine and haloperidol decanoate) and 2 atypicals (risperidone LAI and paliperidone palmitate) are available in the US as LAI formulations. Clinicians need a wider range of long-acting depot compounds to choose from within the atypical range of antipsychotics as, at present, only 1 atypical is available as a LAI antipsychotic. Risperidone LAI and paliperidone LAI are closely related to the same molecule.
Eli Lilly has developed a long-acting depot formulation of olanzapine, olanzapine pamoate (Zyprexa ® Relprevv  ), which has been approved by the Food and Drug Administration (FDA) and introduced in the US in 2010. We will review in the following sections its pharmacology and mode of action, its efficacy and safety profile and its place among the present second-generation LAI formulations.
Methods
The terms olanzapine pamoate and olanzapine long-acting injectable were systematically searched for on pubmed as well as on www.clinicaltrials.gov up to September 2009. In addition, the FDA website http://www.dfda.gov was queried for any available data on these topics. Finally, the Eli Lilly website was reviewed for any additional reported data on olanzapine pamoate. 4 entries on www.clinicaltrials.gov [9] [10] [11] [12] and 8 abstracts of poster presentations. [13] [14] [15] [16] [17] [18] [19] [20] It is important to note that until September 2009 few peer reviewed publications were available on the efficacy and safety of olanzapine pamoate, which somewhat limits this review.
Pharmacology and mode of action
Olanzapine LAI is the salt of pamoic acid and olanzapine that is suspended in an aqueous solution and is injected into the gluteal muscle. 19 Once injected in the gluteal muscle, the two components of the salt slowly dissociate into separate molecular compounds, olanzapine and pamoic acid. The rate of dissolution of the salt is slow, allowing for a gradual release of olanzapine into the circulation over 2 to 4 weeks. 9 Other depot antipsychotic preparations use different mechanisms in order to achieve a slow absorption over time. A number of first-generation LAI antipsychotics possess a terminal alcohol (-OH) group, which allows them to be combined with carboxylic acids by a process of esterification. Long-chain esters show high oil solubility and low water solubility. Long-acting injectable formulations of these drugs contain long-chain drug esters (eg, decanoate) dissolved in a vegetable oil. When injected intramuscularly, the oil forms a depot of drug: the drug ester slowly diffuses into the blood stream and is then rapidly hydrolyzed to release the parent drug. Most second-qeneration antipsychotics lack terminal -OH groups suitable for esterification. Modification of release characteristics is brought about by other means: encapsulating the drug into a biodegradable polymer (risperidone) or injecting a suspension (ie, water-insoluble particulate matter in water) of drug compound (olanzapine). 21 The optimal time to peak concentration should be short to minimize the need for bridging with oral antipsychotic. Risperidone LAI (Risperdal ® Consta ® ; Janssen Pharmaceuticals Ltd) uses microspheres which dissolve gradually and release the active compound into circulation. The absorption is slow and only reaches peak plasma levels after 2 weeks and requires therefore a transition with oral risperidone for 2 weeks initially. The absorption of paliperidone LAI is based on the palmitate ester of paliperidone, which is an aqueous suspension utilizing nanocrystal molecules. This formulation increases its surface area and leads to initial rapid medication release and in a short time to steady state. Active paliperidone plasma levels are detected systemically at day one. The slow rate of dissolution of paliperidone palmitate results in a longer halflife that ranges from 25 to 49 days, allowing a once-monthly intramuscular injection schedule. The first-generation antipsychotics haloperidol and prolixin use ester formations with a decanoate, which dissolve slowly over time. 
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Pharmacokinetics
The doses of olanzapine LAI were chosen based on pharmacokinetic and safety results of phase I studies. 9, 13, 19 Specific pharmacokinetic data have been reported in an open label study in 282 stable patients with schizophrenia. 3 Patients received doses of olanzapine LAI at 100 mg, 150 mg, 160 mg, 200 mg and 300 mg every 2 weeks, and at 210 mg, 255 mg, 300 mg and 405 mg every 4 weeks for 24 weeks. Olanzapine plasma concentrations increased 2-to 3-fold with multiple dosing reaching eventually steady state after about 3 months of dosing. Olanzapine plasma concentrations were sustained throughout the 2-and 4-week injection intervals. Maximum olanzapine plasma concentrations and area under the concentration vs time curve were proportionate to the LAI dose. Time to peak concentration after the injection was 4 days with a half-life of approximatively 26 days. This is an important pharmacokinetic feature as the time to onset of action after an injection is an important criterion for the clinician. The distribution of olanzapine plasma concentration after olanzapine LAI doses of 210 mg every 2 weeks, 300 mg every 2 weeks and 405 mg every 4 weeks were within the 10th and 90th percentiles of the range of olanzapine plasma concentrations found with the olanzapine oral formulation dosed at 5 mg once daily (10th percentile) and 20 mg once daily (90th percentile). Going from oral to olanzapine LAI, Gulliver et al 19 recommend the following conversion strategies: for patients stabilized on 10 mg per day of oral olanzapine the starting olanzapine LAI dose should be 210 mg every 2 weeks or 405 mg every 4 weeks. The patient can then be reduced after 2 months to a lower maintenance dose of 150 mg every 2 weeks or 300 mg every 4 weeks. For patients stabilized on 15 mg of oral olanzapine the starting olanzapine LAI dose should be 300 mg every 2 weeks, which after 2 months can be reduced to 210 mg or 405 mg every 4 weeks. For patients stabilized on 20 mg of oral olanzapine the starting dose of olanzapine LAI should be 300 mg every 2 weeks and should remain at that level, if clinically indicated.
The olanzapine pamoate salt dissolves much more rapidly when it is in contact with a larger amount of blood or plasma, resulting in the release of a large amount of olanzapine over a shorter period of time. Therefore, if olanzapine LAI is accidentally injected into vascular or capillary rich tissue, this property can result in very high olanzapine plasma levels rapidly after the injection with significant clinical acute morbidity. This observation underlies the post-injection delirium/sedation syndrome (PDSS) seen in the context of use of olanzapine LAI. It has been observed in clinical trials and will be reviewed below.
Receptor binding data
Mamo et al 6 reported results on a study examining D(2) receptor occupancy of olanzapine LAI during a multicenter, open-label study exploring D(2) receptor occupancy of a fixed dose of olanzapine LAI given every 4 weeks. Patients with schizophrenia or schizoaffective disorder previously stabilized on oral olanzapine were switched to olanzapine LAI 300 mg by intramuscular injection every 4 weeks for 6 months. No within-group significant changes were found in scores of the Brief Psychiatric Rating Scale Total or in the Clinical Global Impressions-Severity of Illness score, although 7 patients received oral olanzapine supplementation during the first four injection cycles. To minimize impact on D(2) occupancy by the supplemental oral olanzapine, positron emission tomography (PET) scans were not completed during injection cycles that required supplemental oral olanzapine. Mean striatal D(2) receptor occupancy, as measured by [(11) C]-raclopride PET, was 69% on oral olanzapine (5-20 mg/day) and 50% (trough) on olanzapine LAI at steady state. Following an initial decline, occupancy returned to 84% of baseline oral olanzapine occupancy after 6 injections. Over the study period, D(2) receptor occupancy and plasma olanzapine concentrations were significantly correlated (r = 0.76, P = 0.001). Olanzapine LAI resulted in mean D(2) receptor occupancy of approximately 60% or higher at the end of the 6-month study period, 6 ,22 a level consistent with antipsychotic efficacy and also found during treatment with oral olanzapine. However, supplemental oral olanzapine or another dosing strategy may be necessary to maintain adequate therapeutic response during the first few injection cycles.
Efficacy and safety studies Acute treatment
One large, double-blind, placebo controlled, 8-week study of olanzapine LAI in 404 inpatients with acute schizophrenia patients compared 210 mg every 2 weeks, 300 mg every 2 weeks, 405 mg every 4 weeks and placebo in a 1:1:1:1 randomized design. 5 All three olanzapine doses separated significantly from placebo on the total Positive and Negative Syndrome Scale (PANSS). The two higher doses separated from placebo on the PANSS at day 3, while all three doses separated at day 7 from placebo. Discontinuation rates were 32% for the 210 mg dose, 33% for the 300 mg dose, 28% for the 405 mg dose and 43% for the placebo group. The
Lindenmayer Dovepress submit your manuscript | www.dovepress.com Dovepress mean daily benzodiazepine dose used during the trial was not statistically significantly different in the four treatment groups. There were no in-between group differences in the incidence of use of anticholinergics between the four groups; 8.2% of the placebo group patients received anticholinergics, while 5.0% to 12.3% of the olanzapine LAI group patients received anticholinergics. Sedation and increased appetite were more frequently reported for the 300 mg group than for the placebo group. The three olanzapine groups showed a significantly higher change in mean weight gain compared to placebo (3.2-4.8 vs 0.3 kg; P  0.001), a significantly greater increase in fasting cholesterol values as compared to placebo (5.5-10.4 vs -7.0 mg/dL; P  0.15) and a significantly greater increase in fasting triglycerides in the 210 mg and the 400 mg groups compared to placebo (26.3-30.3 vs -9.4 mg/mL; P  0.16), but not for the 300 mg group (17.6 mg/dL; P = 0.55). Few injection site reactions were reported and no patient dropped out of the study because of injection site reaction.
In a more recent post-hoc comparison of these study results with a corresponding set of three studies of oral olanzapine, haloperidol and placebo in similarly acutely ill patients, olanzapine LAI was found to show a comparable magnitude of symptom reduction compared to patients treated with a dose range of 2.5 mg to 15 mg oral olanzapine during 6 weeks of treatment. It appeared that the incidence of parkinsonism was slightly lower for olanzapine LAI with 2.3% to 6.2%, while it was 7.8% to 18.5% for oral olanzapine and 41.8% to 52.5% for haloperidol. 18 
Maintenance treatment
Olanzapine LAI was compared to oral olanzapine for the maintenance of antipsychotic response in stable outpatients with schizophrenia in a 24-week double-blind study. 7, 14 Patients were assigned in a partial randomization design to the following treatment groups: olanzapine LAI 405 mg every 4 weeks, 300 mg every 2 weeks, 150 mg every 2 weeks (total N = 318) or 45 mg/4 weeks (N = 141) or to oral olanzapine 10 mg, 15 mg, or 20 mg/day (N = 144) without a placebo group. The oral olanzapine group assignment was constrained by whichever oral dose patients had been stabilized on before entering the trial for 4 to 8 weeks. Each of the olanzapine LAI doses was statistically superior to the olanzapine LAI 45 mg every 4 weeks dose group based on time to exacerbation. In addition, the three active olanzapine LAI dose groups showed effective maintenance of response as measured by PANSS scores as compared to the 45 mg/4 week group, which showed a statistically significant worsening. Significant separation between the olanzapine LAI dose groups 300 mg every 2 weeks, 405 mg every 4 weeks, 150 mg every 2 weeks groups versus the 45 mg every 4 weeks group in PANSS total scores was also observed starting at 3, 2, and 11 weeks, respectively, and was maintained through the end of the study (P  0.05). Similar differences between the three active olanzapine LAI dose groups and the 45 mg every 4 weeks dose group were observed for the Brief Psychiatric Rating Scale total, Clinical Global Impressions-Improvement, and Clinical Global Impressions-Severity (CGI-S) scores. Mean baseline to endpoint change in PANSS total score for the oral olanzapine group was -1.7, which was not significantly different from that of the highest olanzapine LAI dose group (300 mg every 2 weeks = -2.2; P = 0.606), but superior to the other olanzapine LAI doses (P  0.01). The pooled 150 mg and 300 mg every 2 weeks olanzapine LAI groups were non-inferior to their corresponding oral olanzapine dose groups in terms of the non-exacerbation rate over 24 weeks (90% vs 93% respectively). Conversely, the three active olanzapine LAI groups (405 mg; 300 mg; 150 mg) showed non-inferiority as compared to the oral olanzapine groups in terms of exacerbation of symptoms.
Treatment related adverse events leading to discontinuation were overall low and comparable over the four olanzapine LAI groups (3.1%, 2.8%, 5.0% and 4.2%). Clinically significant weight gain from baseline to endpoint was approximatively dose related: 15.2%, 20.7%, 16.4% and 8.3%. There were significant increases in total cholesterol and fasting LDL cholesterol in the three active olanzapine LAI groups over the low dose group of 45 mg every 4 weeks, while no significant in-between group differences in change were seen in fasting triglyceride and glucose levels. There was a non-significant increase of shifts from 150 mg/dL to high in fasting triglyceride levels seen in the olanzapine LAI 300 mg every 2 weeks group compared to the other three olanzapine LAI groups. No significant differences in treatment emergent extrapyramidal symptoms were reported between any of the olanzapine LAI dose groups and the overall rate of extrapyramidal symptoms was low throughout the trial. Incidence of injection site reactions was low (2.8%). However, 2 patients treated with olanzapine LAI experienced PDSS following possible inadvertent intravascular injection.
Interim results from another long-term, open-label safety extension study of olanzapine LAI with maximum treatment duration of 190 weeks were recently reported. 15 Patients were 18 to 75 years of age with schizophrenia or schizoaffective disorder (N = 931) who were followed up after completing 1 of 3 randomized, controlled studies During the open-label extension, all patients received flexibly-dosed olanzapine LAI at injection intervals of approximately 2 to 4 weeks. At the time of the report, the rate of study discontinuation was 46.3%. Discontinuation rate at 18 months was 34.3%. The most common reasons for discontinuation were: subject decision (23.4%), adverse event (6.7%), and lost to follow-up (5.7%). Adverse events in 5% of patients were increased weight, insomnia, anxiety, somnolence, headache, and nasopharyngitis. Of note were 26 occurrences of PDSS following possible accidental intravascular injection of a portion of the dose; all of the patients fully recovered within 72 hours.
Mean weight change was +1.88 kg, with 32.1% of patients experiencing clinically significant weight gain. Percentages of patients who showed an increase from normal to high on fasting glucose, random total cholesterol, or random triglycerides were 5.5%, 5.2%, and 14.3%, respectively. Mean CGI-S scores remained stable throughout the open label follow-up of the three studies (2.9 at baseline to 2.8 at endpoint).
Switching studies
Two switching strategies from oral antipsychotics to olanzapine LAI were compared in a recent report:
16,17 a direct switch from the previous antipsychotic to olanzapine LAI versus taper of previous antipsychotic medication during the first 2 weeks of treatment. Analyses were based on 8-month data from an ongoing 2-year open-label study of olanzapine LAI in outpatients considered at risk for relapse (N = 264) who received olanzapine LAI every 4 weeks with a starting dose of 405 mg and flexible dosing thereafter. Investigators, at their discretion, could either directly switch patients or taper their previous antipsychotic medication during the first 2 weeks of treatment. At the time of study entry, 62 patients were receiving typical antipsychotics, 188 were receiving atypical antipsychotics (76 receiving oral olanzapine), and 34 were not receiving any antipsychotic; a total of 16 were on prior injectable antipsychotic medication. Some patients were taking more than one antipsychotic at baseline. Of a total of 264 patients, 150 (56.8%) were switched directly and the rest were tapered. The two groups did not significantly differ in discontinuation rates (direct: 29.3% vs taper: 28.9%, P ∼ 1.0) and there was no significant difference between the two groups on PANSS total score mean change at any visit up to 8 months (direct: -1.5, taper: -3.4, P = 0.785, from a mean baseline of 56.7 [SD = 9.8]). Treatment-emergent adverse events in 5% of patients were: increased weight (10.2%), insomnia (8.3%), anxiety (6.8%), somnolence (6.8%), and increased appetite (5.7%). The switch groups did not significantly differ in mean weight change (P = 0.419), with an average weight gain of 2.0 kg, nor did they significantly differ in terms of laboratory analytes or other safety parameters. There did not appear to be clinically significant differences for those who were directly switched to olanzapine LAI versus those who were tapered.
Post-injection syndrome
A small number of patients have experienced PDSS during the participation in olanzapine LAI trials, which is a serious adverse event. The signs and symptoms include feelings of tiredness, dizziness and fatigue progressing to delirium and or excessive sedation and are probably related to an inadvertent intravascular injection of part or the entire olanzapine LAI dose. In a poster by the manufacturer, all safety data of all completed or ongoing olanzapine LAI trials were pooled up to data lock up to May 31 2008. 20 Twenty-nine cases (in 28 patients) of PDSS were identified and reviewed. The per-injection rate was calculated based on a total of 40,000 injections as 0.07% and a per-patient rate of 1.2%. The cumulative risk of experiencing an episode of PDSS after 1 year of treatment was 07% to 1.2%. The presenting symptoms were consistent with excessive systemic levels of olanzapine LAI, such as sedation, dizziness, confusion, slurred speech, altered gait, weakness, muscle spasms and/or unconsciousness. Two patients experienced significant blood pressure increases, but no other changes in vitals signs were observed. Time to onset varied between 0 to 300 minutes with a mean of 48 minutes. Eighty percent of PDSS events occurred within 1 hour after the injection, 17% occurred between 1 hour to 3 hours and 1 case occurred after 3 hours. 79% of patents experiencing a PDSS event were hospitalized and received either only observational care or supportive medical care. Pharmacokinetic data collected at the time of the event revealed that olanzapine plasma concentrations were much higher than expected relative to the post injection concentration previously collected for the same patients. There was no relationship of the PDSS event and any concomitant medications. All patients recovered completely after 3 to 72 hours. PDSS occurred at any injection time point as it was observed from the first injection to the 66th injection. It is interesting to note that PDSS like events have not been reported with other long-acting depot antipsychotics.
The pathophysiology of the PDSS is most likely related to the observation that the olanzapine pamoate salt dissolves much more rapidly when it is in contact with a larger amount Special precautions need to be taken therefore when using olanzapine LAI. First, proper injection technique needs to used, which includes deep gluteal injection and aspiration of the syringe for 5 seconds in order to verify that no blood is being aspired. In the event of blood being aspired the injection site needs to be changed, the syringe needs to be discarded and a new dose needs to be reconstituted. After the injection the patient needs to be observed for 3 hours at the facility where the injection was administered, and the patient needs to be accompanied home by an informed person. Instructions for the patient need to include information about the symptoms of PDSS, the avoidance of driving or operating machinery. 20 The overall use of olanzapine LAI will probably be limited by the potential occurrence of a PDSS event. The primary settings where olanzapine LAI will be utilized will be settings where the post-injection observation period can be implemented and easily integrated into the usual service delivery process, such as inpatient settings, day hospitals or day programs where patients can be involved in active group activities and are at the same time under observation by a mental health care provider after the injection.
The Committee for Medicinal Products for Human Use in Europe has recommended approval of olanzapine LAI in September 2008, which was subsequently approved by the European Commission for maintenance treatment of adult patients with schizophrenia sufficiently stabilized during acute treatment with oral olanzapine for the European Community countries. In contrast, the FDA has delayed a decision on approval as recently as September 2009. The Agency has requested that Eli Lilly and Company prepare a proposed risk evaluation and mitigation strategy. In February 2009 the FDA had issued a not-approvable letter, saying it required additional information about the risk and cause of excessive sedation observed in some patients. Finally, olanzapine LAI was approved by the FDA with a black box warning in 2010. The specific requirements are that olanzapine LAI must be administered in a registered healthcare facility with ready access to emergency response services. After each injection, patients must be observed at the healthcare facility by a healthcare professional for at least 3 hours. Because of this risk, olanzapine LAI is available only through a restricted distribution program called ZYPREXA RELPREVV Patient Care Program and requires prescriber, healthcare facility, patient, and pharmacy training.
Comparison with other long-acting antipsychotics
No data have yet been published on head-to-head randomized trials comparing olanzapine LAI with other antipsychotic depot preparations. There is, however, a virtual comparison examining completion rates of olanzapine LAI studies and of studies with risperidone (RLAI) in LAI formulations. Completion rates were used as a proxy of overall efficacy during the 12-month open-label treatment of patients with schizophrenia. 8 Two comparisons of 12-month completion rates were made: (1) between the two OLAI and RLAI studies which had the most similar study design and patient characteristics; and (2) in all relevant OLAI and RLAI studies identified. For the first comparison, 12-month completion rates for olanzapine LAI and RLAI were 81.5% and 52.0% (P  0.001), respectively, for the subgroup of the studies, which included the most similar populations with regard to baseline treatment and patient characteristics. For the second comparison, 12-month completion rates were 72.9% and 58.0% (P  0.001), respectively, for all patients included in Study HGKB and a pooled analysis of all relevant RLAI studies. No individual RLAI study had a 12-month completion rate greater than that seen for OLAI. However, these results have to be tempered given the potential imbalance between populations across the selected studies.
Conclusions
This review is somewhat limited by the fact that few peer reviewed publications are as yet available on the efficacy and safety of olanzapine pamoate. Overall, olanzapine LAI appears to be an effective antipsychotic at dosages of 210 mg every 2 weeks, 300 mg every 2 weeks and 405 mg every 4 weeks in patients with acute schizophrenia, and at 150 mg every 2 weeks, 300 mg every 2 weeks and at 405 mg every 4 weeks for the maintenance treatment of stable patients with schizophrenia. Its efficacy is in general comparable to the efficacy seen with oral olanzapine at a corresponding dose. The side effect profile is also comparable to the side effects observed with oral olanzapine, including lower rates of extrapyramidal symptoms, prolactin elevation and cardiovascular side effects, but significant metabolic effects. The latter ones include significant weight gain, lipid abnormalities (increase in cholesterol, low-density lipoprotein cholesteraol levels and triglycerides) and glucose dysregulation. While the injection site adverse events are overall mild, the most significant serious
